Ftivazide manufacturers
- Ftivazide USP/EP/BP
-
- $1.10
-
2026-08-20
- CAS:149-17-7
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Ftivazide Basic information |
| Product Name: | Ftivazide | | Synonyms: | Ftivazide;phthivazid;4-pyridinecarboxylic acid, ((4-hydroxy-3-methoxyphenyl)methylene)hydrazide;Isonicotinic acid vanillylidenehydrazide;isonicotinic acid, vanillylidenehydrazide;phtivazid;vanicid;vanillaberon | | CAS: | 149-17-7 | | MF: | C14H13N3O3 | | MW: | 271.27 | | EINECS: | | | Product Categories: | | | Mol File: | 149-17-7.mol |  |
| | Ftivazide Chemical Properties |
| Melting point | 219-220 °C | | Boiling point | 414.36°C (rough estimate) | | density | 1.2122 (rough estimate) | | refractive index | 1.5700 (estimate) | | pka | 8.65±0.35(Predicted) |
| | Ftivazide Usage And Synthesis |
| Chemical Properties | This product is a light yellow crystalline powder. It is slightly soluble in ethanol and insoluble in water. The melting point of this product is 227-231℃. | | Uses | Isonicotinic Acid Vanillylidenehydrazide exhibits anti-mycobacterial activity against Mycobacterium tuberculosis and anti-microbial activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Candida albicans, and Aspergillus niger.Also, it is derived from Isoniazid (I821450), which is an antibiotic for treatment of Mycobacterium tuberculosis, inhibits mycolic acid biosynthesis. Metabolized by hepatic N-acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. Selectively induces expression of CYP2E1. Reversibly inhibits CYP2C19 and CYP3A4 activities, and mechanistically inactivates CYP1A2, CYP2A6, CYP2C19 and CYP3A4 at clinically relevant concentrations. Antibacterial (tuberculostatic). | | Definition | ChEBI: Ftivazide is a member of phenols and a member of methoxybenzenes. |
| | Ftivazide Preparation Products And Raw materials |
|